Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Pooja, Murthy"'
Publikováno v:
JCO Global Oncology, Vol , Iss 6, Pp 1298-1305 (2020)
PURPOSE As a result of their immunocompromised status associated with disease and treatment, patients with cancer face a profound threat for higher rates of complications and mortality if they contract the coronavirus disease 2019 infection. Medical
Externí odkaz:
https://doaj.org/article/65aab8c8f25f4193b8a1c5eb426d38f7
Autor:
Dong D. Lin, Yunhong Wu, Sudhamshi Toom, Niki Sheth, Kevin Becker, Susan Burdette-Radoux, James D'Silva, Yiwu Huang, Jay Lipshitz, Trishala Meghal, Lan Mo, Pooja Murthy, Philip Rubin, Vijaya Natarajan, Bernadine Donahue, Yiqing Xu
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Background: Cancer patients may carry a worse prognosis with SARS-CoV-2 infection. Most of the previous studies described the outcomes of hospitalized cancer patients. We aimed to study the clinical factors differentiating patients requiring hospital
Externí odkaz:
https://doaj.org/article/5c6f4014447c4fe38bbd2b93c6891cd9
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100346- (2021)
Abstact: Objective: Several factors raise concern for increased risk of COVID-19 in cancer patients. While there is strong support for testing symptomatic patients. The benefit of routine testing of asymptomatic patients remains contentious. We aim t
Externí odkaz:
https://doaj.org/article/9e0a2df444084c29acbca11ab10bfd27
Publikováno v:
JCO Global Oncology
PURPOSE As a result of their immunocompromised status associated with disease and treatment, patients with cancer face a profound threat for higher rates of complications and mortality if they contract the coronavirus disease 2019 infection. Medical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79b41277012cc87e88a20fb79173113b
http://europepmc.org/articles/PMC7456327
http://europepmc.org/articles/PMC7456327
Autor:
Pooja Murthy, Franco M. Muggia
Publikováno v:
ecancermedicalscience
Over the last two decades, discoveries related to the breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) have profoundly changed our understanding and management of hereditary breast and ovarian cancers. The concept of synthetic lethality,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbd3bb2b165f93179ffd62d52efe44df
https://doi.org/10.3332/ecancer.2019.904
https://doi.org/10.3332/ecancer.2019.904
Autor:
Franco M. Muggia, Pooja Murthy
Publikováno v:
Cancer drug resistance (Alhambra, Calif.). 2(3)
Following years in development, poly-adenosyl-ribose polymerase (PARP) inhibitors continue to advance the treatment of ovarian and breast cancers, particularly in patients with pathogenic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89ed0a256dc00e250fac4fe2928282bc
https://pubmed.ncbi.nlm.nih.gov/35582575
https://pubmed.ncbi.nlm.nih.gov/35582575
Publikováno v:
Cancer Treatment and Research Communications
Cancer Treatment and Research Communications, Vol 27, Iss, Pp 100346-(2021)
Cancer Treatment and Research Communications, Vol 27, Iss, Pp 100346-(2021)
Abstact Objective Several factors raise concern for increased risk of COVID-19 in cancer patients. While there is strong support for testing symptomatic patients. The benefit of routine testing of asymptomatic patients remains contentious. We aim to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f995ccae432be8ede1983063832326b4
https://doi.org/10.1016/j.ctarc.2021.100346
https://doi.org/10.1016/j.ctarc.2021.100346
Publikováno v:
Inorganica Chimica Acta. 496:119037
Ovarian cancer treatment became ‘platinum-based’ with the approval of cisplatin by the United States Food & Drug Administration (FDA) in 1979 based on work sponsored by the National Cancer Institute (NCI). The drug proved to be dramatically effec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e21e279b2107a42628bb32a7efb3c8d0
https://doi.org/10.1016/j.ica.2019.119037
https://doi.org/10.1016/j.ica.2019.119037
Autor:
Kelley M. Kidwell, N. Lynn Henry, Daniel F. Hayes, Pooja Murthy, Anne F. Schott, Max S. Wicha, Dafydd G. Thomas, Catherine Van Poznak, Jennifer J. Griggs, Sofia D. Merajver, Jeffrey B. Smerage
Publikováno v:
Cancer Research. 75:P6-08
Introduction: Clinical observation suggests that a subset of patients with HER2+ MBC survive for prolonged periods when treated with Her2-targeting regimens. We hypothesized that we could identify clinical and pathological factors associated with pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::510254dde27b27219b941a20c9280c30
https://doi.org/10.1158/1538-7445.sabcs14-p6-08-50
https://doi.org/10.1158/1538-7445.sabcs14-p6-08-50